Pharmacogenomics and Customized Therapies in Psychiatry
|
|
- Asher Little
- 5 years ago
- Views:
Transcription
1 Pharmacogenomics and Customized Therapies in Psychiatry Toshiyuki Someya,, MD, PhD Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences The efficacy and side effects of psychotropic drugs are highly variable across patients and between human populations. A significant portion of this variation is likely due to individual genetic differences -- both in pharmacokinetic & pharmacodynamic pathways. Customized therapies and the role of genetics on interindividual and interethnic differences in drug response represent an area of growing interest.
2 Initial studies in the field focused on single genes concerning primarily drug metabolism. Increasingly, genetic variability of molecular drug targets and their relevance for psychotropic drug efficacy and safety are being studied. Personalized Medicine The Concept of Drug-Predictive Test Combination Patients with same diagnosis Non-responders 1 and toxic responders Responders and patients not predisposed to toxicity 2 Treat with alternative drug or dose Treat with conventional drug or dose
3 Comprehensive pharmacogenomic study of psychotropic-induced induced adverse effects Antipsychotics-induced adverse effects Weight gain/obesity Glucose intolerance Hyperprolactinemia Abnormal ECG Malignant syndrome Dyskinesia Dystonia Antidepressants-induced adverse effects Digestive symptom Genetic factors: Site of action, Drug metabolism Gender difference Age Life environment Physical illness Establishment of tailor-made pharmacotherapy Health and Labour Sciences Reseach Grants (Research on Psychiatric and Neurological Diseases and Mental Health) Prediction of Clinical Effects and Side Effects of Psychotropics using Genome Information (24~28) Development of Personalized Therapy for Schizophrenia and Mood disorder by Utilizing Genomic Medicine Chief Toshiyuki Someya (Niigata University) Collaborators Sunao Kaneko (Hirosaki University) Norio Ozaki (Nagoya University) Mitsuhiko Yamada (National Center of Neurology and Psychiatry)
4 Relation between Plasma Nortriptyline Levels and Clinical Response Plasma nortriptyline concentration(μg/l) Patients Responders Non-Responders Recommended therapeutic range (Montgomery SA et al, Br Med J 1977) Evidence Suggesting the Existence of Upper Therapeutic End of Plasma Levels for Antidepressants Drug Upper End Clinical Consequence Nortriptyline >15 ng/ml HDRS amelioration score decreases Cardiac conduction delay Imipramine + desipramine >25 ng/ml Response rate is no better than < 125 ng/ml Cardiac conduction delay Increased diastolic blood pressure Amitriptyline + nortriptyline >35 ng/ml >45 ng/ml >1 ng/ml Abnormal EEG changes Increased risk of delirium Coma and/or seizures
5 However, for the newer antidepressants such as the selective serotonin reuptake inhibitors (SSRIs( SSRIs), Therapeutic Drug Monitoring (TDM) and concentration-effect effect relationships have not been uniformly consistent. This does not necessarily indicate that pharmacokinetic factors are not important for response to SSRIs -- but rather, drug concentrations in the blood are unlikely to singularly account for a major portion of variability in SSRI response. Additionally, it is noteworthy that clinical significance of pharmacokinetic variability can be unmasked or discerned more effectively upon joint investigation of genetic or biological variability in molecular targets. Fluvoxamine Study
6 Relationship between Plasma Concentration of Fluvoxamine and Clinical Response (PK-PD PD study) Subjects Entry; 122 depressed outpatients (HAM-D-17 score 14) Stepwise multi fixed-dose design by Fluvoxamine 25 ~ 2 mg/d 12-week; 8 dose tolerant patients Receiver Operating Characteristics (ROC) curve analysis Dose tolerant patients Age (y) 4.3 (14.8) a Gender (male/female) 44 / 36 Baseline HAMD-17 score 2.5 (5.5) a Remitters 39 a Values are given as means (SD).
7 Remission and Non-remission in the Stepwise Fixed-Dose (Initial HAM-D-17 score 2 ) Daily FLV dose Remission (ROC case) Non-remission (ROC case) 25 mg 1 (1) 5 (29) 5 mg 3 (3) 47 (37) 1 mg 6 (6) 41 (37) 15 mg 6 (6) 35 (32) 2 mg 5 (5) 3 (27) Total 21 (21) 23 (162) 1.8 Cumulative remission rate.6.4 Fig. 1. ROC curve showing relationship between remission, non-remission and FLV plasma concentration in HAM-D-17 score 2 group ng/ml (p<.1, χ2 analysis; power=96%) Cumulative non-remission rate (Suzuki et al. J Clin Psychopharmacology, in press)
8 Remission and Non-remission in the Stepwise Fixed-Dose (Initial HAM-D-17 score 2 ) Daily FLV dose Remission (ROC case) Non-remission (ROC case) 25 mg 1 (1) 5 (29) 5 mg 3 (3) 47 (37) 1 mg 6 (6) 41 (37) 15 mg 6 (6) 35 (32) 2 mg 5 (5) 3 (27) Total 21 (21) 23 (162) 1 mg/d FLV group 15 mg/d FLV group Cumulative remission rate Cumulative remission rate ng/ml 79.9 ng/ml Cumulative non-remission rate Cumulative non-remission rate
9 Interindividual Variation of Plasma Concentration of Fluvoxamine (PK study) Plasma concentration of fluvoxamine (ng/ml) Relationship between Daily Dose of Fluvoxamine and Steady-state Plasma Concentration of Fluvoxamine Dose of fluvoxamine (mg/day) (Suzuki et al, submitted)
10 F3C C CH2 CH2 CH2 CH2 O CH3 N O CH2 CH2 NH2 AO Fluvoxamine F3C C CH2 CH2 CH2 CH2 O CH3 N O CH2 COOH deaminated metabolite F3C C CH2 CH2 CH2 CH2 O CH3 N OH side chain cleaved metabolite CYP2D6, CYP1A2 NAT F3C F3C C N O CH2 CH2 CH2 COOH CH2 CH2 AO NH2 O-demethylated metabolite C CH2 CH2 CH2 COOH N O CH2 COOH deaminated and O-demetylatedO metabolite F3C C CH2 CH2 CH2 CH2 O CH3 N O CH2 CH2 NH CO CH3 acetylated metabolite Metabolism of fluvoxamine and enzymes suggested to catalyze the Phase I reactions:cyp isoenzymes, amine oxidase(ao), and N-acetyltransferase(NAT).. (C.Hiemcke,S.Hartter/Pharmacology &Therapeutics 85(2)11-28) Effect of CYP2D6 on the Metabolism of Fluvoxamine (PK predictive test)
11 Spigset O, et al. (Eur( J Clin Pharmacol 1997) Plasma concentrations of fluvoxamine was signigicantly higher in poor metabolizers of dextromethorphan than in extensive metabolizers,, in a study of receiving a single oral dose of 5 mg fluvoxamine. Carrillo JA, et al. (Clin( Pharmacol Ther 1996) Poor metabolizers of debrisoquin had significantly low clearance of fluvoxamine, in another study of receiving a single oral dose of 5 mg fluvoxamine. Ohara K, et al. (Eur( J Clin Pharmacol 23) Plasma concentrations of fluvoxamine divided by daily dose of fluvoxamine per body weight were not affected by CYP2D6*1 genotypes. Daily doses of fluvoxamine ranged from 25 mg/day to 15 mg/day. Gerstenberg G, et al. (Ther Drug Monit 23) There was no significant difference among the patients with no (*1/*1), one (*1/*5 and *1/*1), and two (*5/*1 and *1/*1) mutated alleles in the steady-state state plasma concentrations of fluvoxamine corrected to the mean body weight. Daily doses of fluvoxamine was 2 mg/day. Subjects 87 Japanese inpatients or outpatients treated with fluvoxamine 2 age 65 years old Exclusion: with obvious physical illness smokers ( 2 cigarettes/day) treated with other drugs except benzodiazepines Blood sampling Maintained on the same daily doses of fluvoxamine for at least 2 weeks to obtain steady-state concentrations of fluvoxamine Blood sampling was done 12 hours after the last dosage
12 Genotyping CYP2D6*5 and *1: identified by the polymerase chain reaction (PCR) method The patients are divided into three groups by the number of mutated alleles: mutated allele (*1 / *1) 1 mutated allele (*1 / *5, *1 / *1) 2 mutated alleles (*5 / *1, *1 / *1) Statistical analysis Comparisons were made among genotype groups by Kruskal Wallis analysis at fluvoxamine doses of 25, 5, 1, 15 and 2 mg/day The level of statistical significance: P <.5 Effect of the CYP2D6 on the Plasma Concentration of Fluvoxamine Plasma concentration of fluvoxamine (ng/ml) Figure 2-a. at 25 mg/day P =.12 P = Figure 2-b. at 5 mg/day P =.2 P = Number of mutated alleles of CYP2D6 Bars represent median
13 Effect of the CYP2D6 on the Plasma Concentration of Fluvoxamine Plasma concentration of fluvoxamine (ng/ml) Figure 2-c. at 1 mg/day P = Figure 2-d. at 15 mg/day Number of mutated alleles of CYP2D6 Bars represent median Multidrug resistant transporter (MDR1, ABCB1) The MDR1 is expressed in normal tissues such as liver, kidney, and intestine where it contributes to the elimination of xenobiotics and drugs into bile and urine or limits drug absorption from the gastrointestinal tract. It has been shown that polymorphism C3435T in MDR1 can alter p-glycoprotein conformation and protein activity/substrate specificity (Kimchi-Sarfaty C et al. Science 27). However, there have been few clinical studies investigating effects of the functional status of MDR1 on pharmacokinetics of antidepressants.
14 The structure of MDR1 and location of gene polymorphisms (Sakaeda T. 25) Relationship between MDR1 C3435T genotype and steady-state state plasma concentration of fluvoxamine in the 2 mg/day group P =.19 (Kruskal-Wallis test) 4 P =.31 (Mann-Whitney test) Fluvoxamine level (ng/ml/mg) CC CT TT MDR1 C3435T (Fukui et al. Ther Drug Monit 27)
15 Conclusions CYP2D6 may affect the disposition of fluvoxamine more greatly at lower doses of fluvoxamine but less at higher doses of fluvoxamine. On the contrary, MDR1 had a significant effect on plasma fluvoxamine concentration only at the higher dose of fluvoxamine, likely because of CYP2D6 saturated at these higher doses. This is important because this means that pharmacogenetic association studies may need to consider stratification of study samples by dose as well. Moreover, the degree of genetic contribution may vary with dose genetic contributions need not be uniformly constant across all psychotropic drug doses. Relationship between Clinical Response and Serotonin 1A Receptor Polymorphism (PD predictive test)
16 Effect of the 5HT1A Receptor Genotypes on Treatment Response to Fluvoxamine (%) Reduction in the HAMD-17 scores ** **:P<.1 *:P<.5 * Gly/Gly Gly/Asp Asp/Asp * Schematic model of brain 5-HT system Week Polymorphisms of the 5-5 HT1A receptor gene (Suzuki et al. Pharmacogenomics J 24) Relationship between Side Effects and Polymorphisms in the Serotonin 2A Receptor and CYP2D6 Genes (PD predictive test)
17 Detected alleles by PCR 1 A-1438G of 5-HT2A receptor 2 C195T and Pro16Ser of 5-HT3A receptor 3 Tyr129Ser of 5-HT3B receptor 4 *5 and *1 allele of CYP2D6 5-HT receptors are thought to be associated with the gastrointestinal side effects induced by SSRIs. CYP2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism. Subject 1 patients with depression, who gave the written informed consent Diagnoses M : F 47 : 53 Initial HAMD Score (17item) 2.8 ± 5.1 Major Depressive Disorder n = 85 Adjustment Disorder with D. 7 Depressive Disorder NOS 4 Others 4
18 Effect of the A-1438G A polymorphism of the 5-HT2A 5 receptor gene on gastrointestinal side effects induced by fluvoxamine Cumulative Incidence of Gastrointestinal Side Effects G/G A/G A/A 4 HR 2.895, p<.1 HR 2.214, p< Week 12 Polymorphisms of the 5-HT2A 5 receptor gene (Suzuki et al. Neuropsychopharmacology 26) Effect of the CYP2D6 genotype Combination effect of the 5-HT2A 5 receptor and the CYP2D6 gene polymorphism Cumulative Incidence of Gastrointestinal Side Effects HR=1.82, p< Lower Metabolizers (LMs).6.5 Normal Metabolizers (NMs) Week HR=4.24, p< Week LMs with G/G NMs with G/G NMs with A/A 1 12 (Suzuki et al. Neuropsychopharmacology 26)
19 Conclusion There were six LMs of CYP2D6 who had the G/G genotype of the 5-HT2A receptor gene, and all of them suffered from gastrointestinal side effects. Among 11 LMs of CYP2D6 who had the A/G genotype, nine (81.8%) suffered from gastrointestinal side effects. In clinical situations, taking account of these results, tailormade pharmacotherapy for fluvoxamine based on genetic factors may be possible. Paroxetine Study
20 Relationship between Side Effects and Polymorphisms in the Serotonin 3A and 3B Receptor Genes (PD predictive test) Subjects Seventy-eight Japanese psychiatric patients, who gave the written informed consent were included in this study. M : F 28:5 Age 38.4±13.8(range 18~7 years) Diagnoses Major depressive disorder 39 Anxiety disorder 25 Adjustment disorder 6 Depressive disorder NOS 7 Other mood disorder 1
21 Study design The patients visited the hospital every 2 weeks and side effects, including nausea, were assessed at each visit. The paroxetine dose was increased from 1 or 2 mg/day to 3 and 4 mg/day in response to clinical symptoms. We rated the side effects during the last 2 weeks and evaluated the severity of nausea according to our original scale which included five graded items. Subjects with a score of or 1 were defined as subjects without nausea, and those with a score or 2, 3 or 4 were defined as having nausea. Genotyping Polymerase chain reaction was used to determine 1 C195T and Pro16Ser polymorphisms of HTR3A (Niesler et al, 21) 2-1_-12AAG Ins/Del and Tyr129Ser polymorphism of HTR3B (Tremblay et al, 23) 3 CYP2D6*1, *2, *5 and *1 alleles (Johansson et al, 1994 and Steen et al, 1995)
22 Polymorphisms of HTR3B G>A Ala154Ala AAG deletion -1_-12 A>C Tyr129Ser CA deletion 27721_27722 G>A Ala223Thr G>A -3 C>T G>A A>G A>T C>T G>A T>A Chromosome 11q 23.1 Relationship between the HTR3B gene polymorphism and nausea HTR3B Tyr129Ser Tyr/Tyr Tyr/Ser Ser/Ser Tyr/Ser + Ser/Ser Sex ( M/F ) 16/19 1/26 2/5 12/31 P Age ±SD P Nausea + (n=15) (%) ( 73.3 ) ( 26.7 ) (. ) ( 26.7 ) Nausea - (n=63) (%) ( 38.1 ) ( 5.1 ) ( 11.8 ) ( 61.9 ) P.38 *.14 * Sugai et al.: The Pharmacogenomics Journal, 26
23 Logistic regression analysis of independent variables to nausea Independent variable Partial regression coefficients P Odd ratio (95% confidence interval) Sex ( ) Age ( ) Daily dose of Paroxetine ( ) HTR3B Tyr129Ser genotype ( ) Sugai et al.: The Pharmacogenomics Journal, 26 Relationship between the HTR3A gene polymorphisms and nausea HTR3A Pro16Ser HTR3A C195T Pro/Pro Pro/Ser Ser/Ser C/C C/T T/T Sex ( M/F ) 23/34 5/13 /3 15/22 11/16 1/9 P Age ±SD P Nausea + (n=15) (%) ( 8. ) ( 2. ) (. ) ( 6. ) ( 33.3 ) (.7) Nausea - (n=63) (%) ( 71.4) ( 23.8 ) ( 4.8 ) ( 44.4 ) ( 34.9 ) ( 14.3 ) P Sugai et al.: The Pharmacogenomics Journal, 26
24 Relationship between the CYP2D6 gene polymorphism and nausea CYP2D6 *1/*1 *1/*5, *1/*1 *5/*1, *1/*1 Sex ( M/F ) 17/34 5/7 6/9 P.87 Age ±SD P Nausea + (n=15) (%) (17.6) (16.7) ( 26.7 ) Nausea - (n=63) (%) ( 82.4 ) ( 83.3 ) ( 73.3 ) P.716 Sugai et al.: The Pharmacogenomics Journal, 26 H N CH2 O O O CYP2D6 H N CH2 O OH OH F H N Paroxetine CH2 OH O O CH3 H N COMT CH2 O CH3 O OH F Unstable intermediate H N? CH2 OH F Metabolite II F Metabolite I F Metabolite III glucuronide glucuronide and sulfate glucuronide Metabolism of paroxetine and enzymes suggested to catalyze the Phase I reactions: CYP2D6 and catechol-o-methyltransferase(comt).. (C.Hiemcke,S.Hartter/Pharmacology &Therapeutics 85(2)11-28)
25 Relationship between daily dosage of PRX and steady-state state plasma concentration Plasma Paroxetine Level (ng/ml) Dose (mg/day) (Sawamura et al, Eur J Clin Pharmacol 24) Relationship between CYP2D6 genotype and steady-state state plasma concentration of paroxetine in the 1 mg/day group. Plasma Paroetine Level (ng/ml) P<.1 P<.1 *1/*1 *1/*1 *1/*1 *1/*5,*5/*1 CYP2D6 genotype (Sawamura et al, Eur J Clin Pharmacol 24)
26 Clinical Pshychopharmacology Research in Our Group Antipsychotics Antidepressants Pharmacokinetics (PK) # of papers Interindividual variability 9 haloperidol 4,9), timiperone 25), bromperidol 44) amitriptyline 12), clomipramine 13), nortriptyline 43), desipramine 47), paroxetine 83) Metabolic pathway/ Enzyme 2 bromperidol 8,42) Drug interaction 5 haloperidol 29,32,58) fluvoxamine 68,86) Development of TDM kit 2 sultopride 55), haloperidol & bromperidol 79) Pharmacodynamics (PD) 4 bromperidol 44), olanzapine 17) amitriptyline 19), fluvoxamine 138) PK Predictive Test CYP2D6 1 haloperidol 39,58,72) clomipramine 6), amitriptyline 64), nortriptyline 43), desipramine 47), paroxetine 83) CYP2C19 2 clomipramine 6), amitriptyline 64), fluvoxamine 68,86) CYP1A2 1 haloperidol 61) ABCB1 (MDR1) 1 fluvoxamine 116) PD Predictive Test 3 fluvoxamine 77,95), paroxetine 13) Pharmacotherpy based on Pharmacogenetics & TDM Diagnosis (DSM-IV-TR) Pharmacodynamic Predictive Test 5-HTTLPR(S allele, L allele) 5-HT1A(Gly272Asp, -119C/T) 5-HT2A(-1438A/G, 12T/C) 5-HT3B(Tyr129Ser) Pharmacokinetic Predictive Test CYP2D6 genotype CYP2C19 genotype CYP1A2 genotype ABCB1(MDR1) genotype (C3435T) Prediction of Drug Efficacy Prediction of Adverse Drug Reaction Treatment Decisions (to prescribe the right drug, at the right dose, for the right patient) Therapeutic Drug Monitoring (clinical effect, side effect, plasma drug concentration) Ono S, Suzuki Y, Someya T. Japanese Journal of Psychiatric Treatment, 28
Mental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationTherapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Prof. Dr. Christoph Hiemke Psychiatrische Klinik und Poliklinik Universität Mainz Psychopharmacotherapy Psychiatric Patient
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationPsychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D.
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationPharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationAre health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies
Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies David Gurwitz Sackler Faculty of Medicine, Tel-Aviv University, Israel OECD,
More informationPharmacogenetics of Selective Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions
Pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions Kelan L. H. Thomas, Pharm.D., and Vicki L. Ellingrod, Pharm.D., FCCP The selective serotonin reuptake inhibitors
More informationPharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )
Pharmacogenetic Testing in Psychiatry Jose de Leon, MD (12-01-15) Conflicts of Interest (See more details on conflict of interest in the first presentation Training Psychiatrists to Think like Pharmacologists
More informationPharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects
Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects Dr. Francisco Abad Santos 16 June 2017 Atypical antipsychotics or second generation antipsychotics
More informationPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
(2004) 9, 442 473 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp FEATURE REVIEW Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic
More informationCYP2D6: mirtazapine 2001/2002/2003
CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =
More informationMujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon
Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon State Hospital, Salem Oregon Assurex Health Inc. has
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationBiomarkers for Psychiatric Drug Toxicity. Oct 24, 2008 Thomas R. Insel, M.D. Director, NIMH
Biomarkers for Psychiatric Drug Toxicity Oct 24, 2008 Thomas R. Insel, M.D. Director, NIMH Burden of Disease (DALYs) U.S., Canada, and Western Europe 15-44 years old Mental Illness* Injuries, including
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationRisperidone Case 1: Drug-Drug Interactions
Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationETHNICITY AND PSYCHOTROPIC RESPONSE
Ethnic Differences in Drug Metabolism ETHNICITY AND PSYCHOTROPIC RESPONSE Bridging Cultures: Improving Evaluation & Treatment of Cognitive 8 March 28 Keh-Ming Lin, M.D., M.P.H. Professor Emeritus of Psychiatry,
More informationPharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
More informationPharmacogenomics and Cultural Issues! Y. W. Francis Lam, Pharm.D., FCCP!
Pharmacogenomics and Cultural Issues in Psychopharmacology Y. W. Francis Lam, Pharm.D., FCCP 1 Pharmacogenomics and Cultural Issues in Psychopharmacology Y. W. Francis Lam, Pharm.D., FCCP Professor of
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Mental Health Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_mental_health_conditions 1/2014 6/2017 6/2018
More informationSafe and Effective Use of. Psychotropic Drugs. Introduction. Psychotropic Drugs. Jun NAKAMURA
Psychotropic Drugs Safe and Effective Use of Psychotropic Drugs JMAJ 47(6): 259 264, 2004 Jun NAKAMURA Professor, Department of Psychiatry, School of Medicine, University of Occupational and Environmental
More informationTwo decades of clinical pharmacogenetic testing - Where do we stand?
Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden
More informationSelf Assessment Question 1
Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1 Self
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationMycophénolate mofétil
Mycophénolate mofétil O OH CH 3 O O-desmethyl O glucosides OH CH 3 OCH 3 CH 3 CYP 3A UGT2B7 C O HO O HO AcMPAG (acyl-glucuronide) ACTIF TOXIQUE O O CH 3 OCH 3 Mycophenolate (MPA) OH COOH UGT enzymes COOH
More informationMontpellier and Nimes University Hospital. 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs Madrid, September the 13th and 14th
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer Litaty MBATCHI, Matthieu GASSIOT,
More informationImplementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
More informationNew Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center
New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center Background Genetic testing Treatment options: Pharmacogenetics
More informationPsychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing
Psychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing CMS NEWEST GUIDELINES CMS will push nursing homes to reduce their use
More informationOrientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology
Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology Objective: To discuss basic principles of psychopharmacology in children and adolescents. Pharmacokinetics:
More informationRisperidone (RIS) is metabolized primarily by 9-hydroxylation
BRIEF REPORT Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients Rhee-Hun Kang, MD, PhD,* Sun-Min Jung, MD, PhD,þ
More informationGeneral Discussion 4
General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationClinical Pharmacogenomics in Depression Treatment
Clinical Pharmacogenomics in Depression Treatment GORDON ANG, PHARMD PGY- 2 PSYCHIATRIC PHARMACY RESIDENT CENTRAL TEXAS VETERANS HEALTH CARE SYSTEM 1 Abbreviations CGI-S: Clinical Global Impression Severity
More informationThe Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders
Curr Behav Neurosci Rep (2015) 2:154 164 DOI 10.1007/s40473-015-0048-z MOOD AND ANXIETY DISORDERS (D IOSIFESCU, SECTION EDITOR) The Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders
More informationClozapine Case 1 The Relevance of CYP Jose de Leon, MD
Clozapine Case 1 The Relevance of CYP 12-18-15 Jose de Leon, MD 1. Clozapine Case 1 J Clin Psychiatry 1996;57:175-176 http://www.ncbi.nlm.nih.gov/pubmed/8601555 Educational Objectives At the conclusion
More informationSuitable dose and duration of fluvoxamine administration to treat depression
PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT
PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN
More informationYour Kailos Test. Sample ID: CL-4194-DM. Jane Doe DOB: Hello Jane,
1 Jane Doe DOB: 1985-01-05 Sample ID: CL-4194-DM Hello Jane, Thank you for ordering your Kailos test for antidepressants. Kailos Genetics is committed to making gene-based healthcare available to YOU.
More informationPrecision Medicine in Mental Health Care
Precision Medicine in Mental Health Care Study PI: David Oslin, MD 11/21/17 Background: Public Health Significance Depression is one of the world s great public health problems At least 1 in 7 Veterans
More informationPharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik
Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA
More information6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
More informationGenetic Testing for Diagnosis and Management of Mental Health Conditions
Genetic Testing for Diagnosis and Management of Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationPharmacogenetics and Antipsychotic Treatment in Schizophrenia with Special Focus on Adverse Drug Reactions
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 335 Pharmacogenetics and Antipsychotic Treatment in Schizophrenia with Special Focus on Adverse Drug Reactions ARZU
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationPharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants
University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 11-2014 Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants Domenico Italiano University
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationGenomics (HMGP 7620) Pharmacogenomics.
Genomics (HMGP 7620) Pharmacogenomics http://unlockinglifescode.org/explore/genomic-medicine/pharmacogenomics Matthew Taylor MD PhD matthew.taylor@ucdenver.edu Variety is the Spice of Life Current Model:
More informationPharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN
Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationGenetic Testing for Mental Health Conditions
Genetic Testing for Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/01/2015 Section: Medicine
More informationAsian Journal of Modern and Ayurvedic Medical Science ISSN [ONLINE]
Asian Journal of Modern and Ayurvedic Medical Science ISSN 2279-0772 [ONLINE] Volume: volume2,number 1 publication Date: Tuesday, January 01, 2013 Published by Mpasvo [article url http://www.ajmams.com/viewpaper.aspx?pcode=1ea96e49-1604-434e-96ee-6cc8fd946cbb
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationGenetic Testing Patient Guide
Genetic Testing Patient Guide Over the last decade, pharmacogenetics has become increasingly significant to clinical practice. Psychiatric patients, in particular, may benefit from pharmacogenetic testing
More information2. REVIEW OF LITERATURE
2. 3.1 Milnacipran 3.1.1 Pharmacodynamic Properties Depression is thought to be caused by a functional deficit in noradrenergic and/or serotonergic central neurotransmission. [55] Most antidepressants
More information, 73 (2), (2013) * Yuka Moriya DDS. Caspase * Vol. 73, No.
, 73 (2), 111 116 (2013) * Yuka Moriya 3 DDS 3 Caspase 3 *2000 2008 525 8577 1 1 1 E-mail: tomoka@ph.ritsumei.ac.jp 6 2 2 1 Vol. 73, No. 2 (2013) 111 10 CV 4 1 4 MELAS Risk Benefit Benefit % 2001 CsA CsA
More informationEffect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia
Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia Concetta D Arrigo a, Gaetana Migliardi a, Vincenza Santoro a, Letterio Morgante b, Maria Rosaria Muscatello b,
More informationPharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia
Pharmacokinetics Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia The Journal of Clinical Pharmacology 2018, 58(1) 74 80 C 2017,
More informationGenes and environment: The complex etiology of psychiatric disorders
Genes and environment: The complex etiology of psychiatric disorders János Réthelyi, M.D., Ph.D. Department of Psychiatry and Psychotherapy Semmelweis University September 18th 2013 Outline The issue of
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationTable of Contents. Preface Abstract Acknowledgements... 9
Table of Contents Preface... 5 Abstract... 7 Acknowledgements... 9 1. Introduction... 17 1.1 Bipolar Affective Disorder... 17 1.1.1 History and Symptomatology of Bipolar Disorder... 17 1.1.2 Pharmacotherapy...
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationPharmacological treatment of anxiety disorders where is
Pharmacological treatment of anxiety disorders where is the room for improvement? David S Baldwin, Professor of Psychiatry BAP Masterclass, 15 th April 2011 dsb1@soton.ac.uk Declaration of interests (last
More informationPharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference
Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More information3. Atypical antidepressants
3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationPharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017
Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017 Atomoxetine Prescription CYP2D6 Genotype (AS = 0) (AS = 0.5 1.0) (As = 2.0) Ultrarapid (AS >2.0) Standard dose. Dose increase probably not necessary;
More informationPlasma ammonia levels in patients treated with valproic acid
Research Plasma ammonia levels in patients treated with valproic acid Hirofumi Tesen 1, Asuka Katsuki 1, Hikaru Hori 1, Kiyokazu Atake 1, Reiji Yoshimura,1, Jun Nakamura 1 ABSTRACT Objective: Valproic
More informationPharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC)
Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC) Laura Ramsey, PhD Co-Director, Genetic Pharmacology Service Assistant Professor Divisions of Research in Patient
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytochrome p450 Genotyping Page 1 of 24 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: See Also: Cytochrome p450 Genotyping Genetic Testing for Helicobacter
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationClinically Relevant Interactions between Newer Antidepressants and Second-Generation Antipsychotics
University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 5-2014 Clinically Relevant Interactions between Newer Antidepressants and Second-Generation Antipsychotics Edoardo Spina University
More informationSafety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents
Pediatr Drugs (2013) 15:217 233 DOI 10.1007/s40272-013-0024-6 REVIEW ARTICLE Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents Silvio Caccia Published online: 16 April
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationAssociation of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study
Ito et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:28 https://doi.org/10.1186/s40780-018-0126-y RESEARCH ARTICLE Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia
More informationI have NO actual or potential conflicts of interest in relation to this educational presentation.
Genotyping The Patient Requiring Mental Health Medications: When Does It Make Sense? Charles F. Caley, PharmD, BCPP Clinical Professor UConn School of Pharmacy Storrs, CT I have NO actual or potential
More informationImpact of CYP2C19 genetics on pharmacokinetic variability of escitalopram and sertraline - a study based on therapeutic drug monitoring data
Impact of CYP2C19 genetics on pharmacokinetic variability of escitalopram and sertraline - a study based on therapeutic drug monitoring data Ida Rudberg 2009 Department of Psychopharmacology Diakonhjemmet
More informationNew Medications in Early Psychosis
New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,
More informationEffect of Co-medication on the Serum Concentrations of Aripiprazole and the Main Metabolite Dehydroaripiprazole
Effect of Co-medication on the Serum Concentrations of Aripiprazole and the Main Metabolite Dehydroaripiprazole Thesis submitted for the degree Candidate Pharmaciae at Department of Pharmaceutical Biosciences,
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationMedical Policy. MP Genetic Testing for Mental Health Conditions
Medical Policy MP 2.04.110 BCBSA Ref. Policy: 2.04.110 Last Review: 06/22/2017 Effective Date: 06/22/2017 Section: Medicine End Date: 06/26/2018 Related Policies 2.04.38 Cytochrome p450 Genotyping 2.04.82
More informationDisclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015
49th Annual Meeting Psychiatry for the Non-Psychiatry Specialist Jacintha Cauffield, PharmD, BCPS, CDE Associate Professor of Pharmacy Practice Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University
More informationImipramine therapy (CYP2D6)
Imipramine therapy (CYP2D6) Intake Start therapy 1st conc 08:00 2nd conc 3e spiegel 4e spiegel 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients need dose adjustment Imipramine therapy (CYP2D6) Intake
More informationObjectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
More information